OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Sanofi and Seagen have entered an agreement to investigate three cancer targets.
Sanofi and Seagen announced on March 16, 2022, an exclusive collaboration agreement to design, develop, and commercialize novel antibody-drug conjugates (ADCs). The companies will use Sanofi’s monoclonal antibody technology and Seagen’s ADC technology to investigate up to three cancer targets.
“This collaboration will enable the synergistic combination of molecules and platforms to produce candidate medicines with the potential of bringing renewed hope to cancer patients and their families,” said John Reed, global head of R&D, Sanofi, in a company press release. “We look forward to joining forces with Seagen to collaboratively design and develop promising medicines by advancing antibody-drug conjugate science.”
“We are excited to be working with Sanofi, a global biopharmaceutical leader, to identify new ways to potentially address unmet medical needs of cancer patients,” said Clay Siegall, president and CEO, Seagen, in the press release. “Jointly developing novel ADCs by combining antibodies from Sanofi with Seagen’s proprietary ADC technology, aligns with our strategic priorities to expand the global potential of our pipeline with new first- or best-in-class programs.”
Per the terms of the agreement, the companies will co-fund global development and equally share any resulting profits. Additionally, Sanofi will make an undisclosed payment to Seagen for each of the three targets as they are selected. According to the press release, Sanofi has already selected the first target.